Advertisement
ABBV vs AMGN
Which Stock Would AI Choose? AbbVie Inc. (ABBV) vs. Amgen Inc. (AMGN) Stock Comparison
Key Takeaways
- AbbVie (ABBV) has outperformed Amgen (AMGN) year-to-date (YTD), with returns of approximately 11.6% compared to AMGN's 6.0%.
- ABBV offers a higher dividend yield at 3.48% versus AMGN's 2.93%, appealing to income-focused investors.
- Recent FDA feedback on ABBV's aesthetics candidate introduced short-term volatility, while AMGN advances AI-driven leadership changes.
- AMGN trades at a lower price-to-earnings (P/E) ratio of 24.2 versus ABBV's 84.2, suggesting potentially better value on earnings multiples.
- Both stocks exhibit low beta values (ABBV 0.36, AMGN 0.47), indicating relative stability amid market fluctuations.
Introduction
AbbVie Inc. (ABBV) and Amgen Inc. (AMGN) stand as pillars in the biopharmaceutical sector, both delivering innovative therapies in immunology, oncology, and beyond. This comparison analyzes their recent market performance, growth drivers, and risk profiles amid evolving healthcare demands and regulatory landscapes. Dividend-seeking investors, growth-oriented traders, and those eyeing defensive healthcare plays in uncertain markets will find value in understanding their relative positioning, momentum, and upcoming catalysts like quarterly earnings.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a global biopharmaceutical leader focused on immunology (e.g., Skyrizi, Rinvoq), oncology, neuroscience, aesthetics (e.g., Botox), and eye care. In recent market activity, ABBV shares have shown resilience, trading around $199 with a market capitalization exceeding $350 billion. Year-to-date gains of about 11.6% reflect steady demand for core products post-Humira patent expiration, bolstered by acquisitions like Cerevel and ImmunoGen. Sentiment dipped briefly on a Complete Response Letter (CRL) from the FDA for its trenibotulinumtoxinE wrinkle treatment due to manufacturing issues—no safety concerns noted—but analysts like Piper Sandler raised price targets ahead of earnings, signaling confidence in pipeline momentum.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) develops human therapeutics targeting oncology, inflammation, cardiovascular, and rare diseases, with key products like Enbrel, Prolia, Repatha, and Otezla. Shares recently hovered near $345, with a market cap of roughly $186 billion. YTD performance stands at 6.0%, trailing broader gains but supported by strong one-year returns around 27%. Recent weeks featured leadership shifts emphasizing AI integration, alongside preparations for quarterly results. While stock slides occurred amid market rises, high return on equity (over 100%) and robust free cash flow underscore operational strength, though earnings expectations reflect potential moderation.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from its library of 351 AI trading bots, which generate real-time signals across thousands of stocks, ETFs, and cryptocurrencies. Only 25 bots earn a spot here, selected for superior adaptation to current volatility, showcasing annualized returns from +15% to +168%, win rates of 48% to 88%, and profit factors up to 11.7 across strategies like short-term scalping (15-60 minutes) and longer holds. Themes include semiconductors, aerospace, and gold miners, with multi-agent systems trading 3-25 tickers. These bots employ diverse styles—momentum, mean reversion, risk-managed—for automated copy trading. Investors can explore performance stats and integrate with brokerages for hands-free execution tailored to market conditions.
Head-to-Head Comparison
Both ABBV and AMGN operate similar biopharma models, emphasizing high-margin specialties like immunology and oncology, but diverge in growth drivers: ABBV leans on immunology blockbusters and aesthetics for post-patent stability, while AMGN pushes biosimilars, obesity candidates, and AI-enhanced R&D. Recent momentum favors ABBV's YTD edge, yet AMGN's lower P/E and superior one-year gains highlight valuation appeal. Risk factors include patent cliffs and FDA scrutiny—ABBV's recent CRL versus AMGN's liver injury warnings on niche drugs. Sector exposure aligns in healthcare defensiveness (low betas), but market sentiment tilts toward ABBV's dividend allure amid ABBV's larger scale versus AMGN's efficiency metrics like higher ROE (return on equity).
Tickeron AI Verdict
Tickeron’s AI currently favors ABBV over AMGN, driven by stronger trend consistency, elevated dividend yield, and positive analyst revisions ahead of earnings. ABBV's relative stability and YTD outperformance position it probabilistically better for near-term momentum in a volatile biotech landscape, though AMGN's value metrics warrant monitoring for shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and AMGN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileAMGN’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- AMGN’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while AMGN’s TA Score has 5 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- AMGN’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +4.37% price change this week, while AMGN (@Pharmaceuticals: Major) price change was +3.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.22%. For the same industry, the average monthly price growth was +2.11%, and the average quarterly price growth was +2.84%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
AMGN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.22% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | AMGN | ABBV / AMGN | |
| Capitalization | 401B | 189B | 212% |
| EBITDA | 16.9B | 16.7B | 101% |
| Gain YTD | 1.080 | 8.356 | 13% |
| P/E Ratio | 111.39 | 24.33 | 458% |
| Revenue | 62.8B | 37.2B | 169% |
| Total Cash | 9.39B | 12B | 78% |
| Total Debt | 72.9B | 57.3B | 127% |
ABBV | AMGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 10 | 24 | |
SMR RATING 1..100 | 1 | 12 | |
PRICE GROWTH RATING 1..100 | 46 | 48 | |
P/E GROWTH RATING 1..100 | 22 | 60 | |
SEASONALITY SCORE 1..100 | 5 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (6) in the Biotechnology industry is in the same range as ABBV (11) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is in the same range as AMGN (24) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (12) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as AMGN (48) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's P/E Growth Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (60) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than AMGN’s over the last 12 months.
| ABBV | AMGN | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 26% | 4 days ago 68% |
| Stochastic ODDS (%) | 4 days ago 45% | 4 days ago 40% |
| Momentum ODDS (%) | 4 days ago 67% | 4 days ago 54% |
| MACD ODDS (%) | 7 days ago 60% | 4 days ago 56% |
| TrendWeek ODDS (%) | 4 days ago 59% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 61% | 4 days ago 56% |
| Advances ODDS (%) | 4 days ago 57% | 4 days ago 56% |
| Declines ODDS (%) | 8 days ago 48% | 7 days ago 52% |
| BollingerBands ODDS (%) | 4 days ago 42% | 4 days ago 51% |
| Aroon ODDS (%) | 4 days ago 65% | 4 days ago 54% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +1.15% | ||
| BIIB - AMGN | 62% Loosely correlated | -0.57% | ||
| BMY - AMGN | 57% Loosely correlated | +1.18% | ||
| NVS - AMGN | 53% Loosely correlated | +0.51% | ||
| PFE - AMGN | 52% Loosely correlated | +1.36% | ||
| GSK - AMGN | 52% Loosely correlated | +0.49% | ||
More | ||||